Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ovarian Cancer Risk May Be Paternally Inherited

By LabMedica International staff writers
Posted on 01 Mar 2018
A history of ovarian cancer among first-order relatives remains the strongest and best-characterized predictor of ovarian cancer risk and a main determinant of genetic testing referral.

The evidence for a monogenic, autosomal dominant mode of inherited risk dates to the pre- breast cancer 1, early onset gene (BRCA) era where studies focused on assessing heritability using affected first-order and second-order female relatives.

Scientists at Roswell Park Cancer Institute (Buffalo, NY, USA) and their colleagues first identified 3,499 grandmother-granddaughter pairs from a familial ovarian cancer registry that encompassed information on more than 50,000 individuals from 2,600 families collected over several decades. More...
They whittled this set down to the 892 pairs, providing clues to ovarian cancer risk transmission, which included 157 granddaughters with ovarian cancer.

In an effort to tease out the basis of this X-linked inheritance, the scientists did exome sequencing on 159 BRCA1/2 mutation-negative women from the registry, focusing on germline X chromosome and BRCA1 coding sequences. The group included 49 ovarian cancer-affected women with affected mothers, 46 cases who had an affected sister and unaffected mother, and seven ovarian cancer-affected women with an affected sister and mother.

The team found that overlapping ovarian cancer diagnoses were more common in the paternal grandmother-granddaughter pairs, where the cancer rate was more than 28% than in the pairs involving maternal grandmothers and their granddaughters. The latter pairs had an ovarian cancer rate just shy of 14%. The presence of ovarian cancer in a paternal grandmother, but not a maternal grandmother, coincided with earlier age of onset in affected granddaughters. They tracked down a missense mutation in the MAGE Family Member C3 (MAGEC3), a gene previously put forward as a potential X-linked tumor suppressor. The variant was in linkage disequilibrium with other nearby variants, suggesting there might be an alternative causal variant or a related haploblock in the X chromosome region identified.

The authors concluded that they had demonstrated that a genetic locus on the X-chromosome contributes to ovarian cancer risk. An X-linked pattern of inheritance has implications for genetic risk stratification. Women with an affected paternal grandmother and sisters of affected women are at increased risk for ovarian cancer.

Kevin H. Eng, PhD, an assistant professor of oncology and the lead author said. “Our study may explain why we find families with multiple affected daughters: because a dad's chromosomes determine the sex of his children, all of his daughters have to carry the same X-chromosome genes.” The study was published on February 15, 2018, in the journal PLOS Genetics.

Related Links:
Roswell Park Cancer Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.